The ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group: Mark Atkinson, University of Florida, Gainesville, FL, USA; Philip Bernstein, Immune Tolerance Network, Bethesda, MD, USA; Jeffrey A. Bluestone, University of California, San Francisco, USA; Andrew Chan, Genentech, South San Francisco, CA, USA; Mario Ehlers, Immune Tolerance Network, San Francisco, CA, USA; Hideki Garren, Bayhill Therapeutics, Palo Alto, CA, USA; Robert Goldstein, Juvenile Diabetes Research Foundation International, New York, NY, USA; Peter Gottlieb, University of Colorado, Denver, CO, USA; Maria Grazia-Roncarolo, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy; Len Harrison, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Kevan Herold, Yale University, New Haven, CT, USA; Scott Koenig, Macrogenics, Rockville, MD, USA; Gerald Nepom, Benaroya Research Institute, Seattle, WA, USA; Mark Peakman, King's College London, London, UK; Bart Roep, Leiden University Medical Center, Leiden, Netherlands; Teodora P. Staeva, Juvenile Diabetes Research Foundation International, New York, NY, USA; Roland Tisch, University of North Carolina, Chapel Hill, NC, USA; Matthias von Herrath, La Jolla Institute of Allergy and Immunology, La Jolla, CA, USA.
1365-2249/asset/cei_left.gif?v=1&s=ffee144c532fe5e73bbb89290ba14e154b0d400b)
1365-2249/asset/cei_right.gif?v=1&s=c14d545a5215173707c8202758d5b25fd0bede44)
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group
Article first published online: 8 APR 2010
DOI: 10.1111/j.1365-2249.2010.04153.x
Journal Compilation © 2010 British Society for Immunology. No Claim to Original US Government Works
Additional Information
How to Cite
Matthews, J. B., Staeva, T. P., Bernstein, P. L., Peakman, M., Von Herrath, M. and the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group (2010), Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clinical & Experimental Immunology, 160: 176–184. doi: 10.1111/j.1365-2249.2010.04153.x
Publication History
- Issue published online: 8 APR 2010
- Article first published online: 8 APR 2010
- Accepted for publication 10 February 2010
- Abstract
- Article
- References
- Cited By
Keywords:
- clinical trials;
- combination therapies;
- interventions;
- type 1 diabetes
Summary
Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes of action. The numerous advantages of such a strategy include the ability to minimize toxicities and realize synergies to enhance and prolong efficacy. The recognition that combinations might offer far-reaching benefits, at a time when few single agents have yet proved themselves in well-powered trials, represents a significant challenge to our ability to conceive and implement rational treatment designs. As a first step in this process, the Immune Tolerance Network, in collaboration with the Juvenile Diabetes Research Foundation, convened a Type 1 Diabetes Combination Therapy Assessment Group, the recommendations of which are discussed in this Perspective paper.